Sarepta Hits Another Roadblock Prior to Eteplirsen New Drug Application
Insights - On Monday morning, Sarepta Therapeutics (SRPT) held a teleconference concerning regulatory updates for Eteplirsen, the company’s lead drug candidate for Duchenne Muscular Dystrophy. In a Type B … Continue Reading
Read Now